Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 315 of 5804
-
Old drug, new trick: vancomycin may stop c. diff before it starts
Prevention Not yet recruitingThe purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics. Participants in this study will be placed randomly into two groups. The oral vancomycin treat…
Phase: PHASE2, PHASE3 • Sponsor: University of Maryland, Baltimore • Aim: Prevention
Last updated Jun 27, 2026 08:08 UTC
-
Freeze and unleash: experimental combo aims to boost immune attack on aggressive breast cancer
Disease control Not yet recruitingSummary Points: 1. High Risk Breast Cancers: Triple negative cancer is considered high risk due to high rate of local and systemic failure. Newer innovative treatment strategies are needed to improve systemic control of disease and survival. 2. Immune system modulation: is an em…
Phase: PHASE1, PHASE2 • Sponsor: Texas Tech University Health Sciences Center • Aim: Disease control
Last updated Jun 26, 2026 15:10 UTC
-
New Three-Drug cocktail aims to fight tough lung cancer
Disease control Not yet recruitingThe study consists of two parts: Part I is a randomized, double-blind, multicenter, parallel-controlled phase II clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with serplulimab and chemot…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody drug aims to ease endometriosis pain in major trial
Symptom relief Not yet recruitingA phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension
Phase: PHASE3 • Sponsor: Hope Medicine (Nanjing) Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Stem cells could save sight after chemical burns
Disease control Not yet recruitingSevere chemical burns of the eye are serious injuries that can cause intense inflammation of the ocular surface and destroy limbal epithelial stem cells, which are essential for corneal healing. These injuries may lead to severe vision loss, blindness, or even loss of the eye des…
Phase: PHASE2 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New shot aims to cut COPD attacks in half
Disease control Not yet recruitingA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase: PHASE3 • Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New CAR-T therapy aims to control Hard-to-Treat lymphoma
Disease control Not yet recruitingThis Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a). The primary endpoint is objective response rate (ORR) …
Phase: PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New scan could catch hidden prostate cancers missed by MRI
Diagnosis Not yet recruitingThis study is a multi-center RCT to compare the clinically significant prostate cancer (csPCa) detection and/or change in clinical management in MRI guided (MRI arm) biopsy and MRI+18F-PSMA guided (Combined arm) biopsies in men with equivocal MRI prostate scans. If additional cli…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
Timing is everything: new trial seeks to boost cancer treatment by scheduling immunotherapy just right
Disease control Not yet recruitingThis is a multicenter, open-label, randomized phase II clinical trial designed to evaluate the optimal timing of toripalimab administration during neoadjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Participants will receive gemcitabine and…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take aim at multiple sclerosis and myasthenia gravis
Disease control Not yet recruitingThis is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells(QT-019C).
Phase: EARLY_PHASE1 • Sponsor: Tianjin Huanhu Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Heart scar on MRI may decide who gets a lifesaving shock device
Disease control Not yet recruitingResearch questions: The value of primary prevention implantable cardioverter-defibrillator implantation (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM) is under debate. Improved risk stratification is needed to select patients at highest risk. Hypotheses: 1. In…
Phase: NA • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Magic mushroom therapy targets depression and alcoholism in new trial
Symptom relief Not yet recruitingThe goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The main question it aims to answer is: \- What is the feasibility and safety…
Phase: PHASE2 • Sponsor: Centre for Addiction and Mental Health • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New antibody combo targets tough lymphoma in early trial
Disease control Not yet recruitingThis is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). The study consists tw…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to shrink ovarian tumors before surgery
Disease control Not yet recruitingThis is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for patients with advanced high-grade serous ovarian ca…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug takes on T-DXd in breast cancer showdown
Disease control Not yet recruitingThis is a single-center, randomized, open-label, phase II interventional study. Eligible patients will be randomized 1:1 to receive either Trastuzumab-rezetecan (4.8 mg/kg Q3W) or T-DXd (5.4 mg/kg Q3W) for 8 neoadjuvant cycles. After completing neoadjuvant treatment, patients wil…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Gene therapy hope for sickle cell: tiny trial tests One-Time fix
Disease control Not yet recruitingIt is a single-arm, single-center, open-label, single-dose study. A total of three subjects with severe sickle cell disease (SCD), aged 12-50 years (inclusive), are planned to receive cell infusion. After successful hematopoietic stem cell engraftment is achieved in the first sub…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New rapid swab test could transform TB diagnosis in remote areas
Diagnosis Not yet recruitingDARE-TB has been designed to address critical evidence gaps on the diagnostic performance and operational value of near point-of-care (NPOC) nucleic acid amplification tests (NAATs) within community-based case finding (CBCF) strategies. Although World Health Organization (WHO) re…
Phase: NA • Sponsor: Liverpool School of Tropical Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
New combo procedure aims to fix heart rhythm and prevent stroke in one go
Disease control Not yet recruitingA multicenter, prospective registry of concomitant Farapulse (Boston scientific) based PVI and Watchman Flx device (Boston scientific) based LAAC procedures was planned in order to assess the acute and mid-time safety, efficacy and efficiency of this approach (COCONUT II study). …
Phase: NA • Sponsor: Asklepios proresearch • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Neck surgery aims to flush Alzheimer's proteins from the brain
Disease control Not yet recruitingOfficial Title Prospective Single-Arm Safety Study of Cervical Lymphaticovenular Anastomosis (LVA) in Patients with Alzheimer's Disease Purpose of the Study Researchers are conducting this study to see if a minimally invasive microsurgery, called Cervical Lymphaticovenular Anast…
Phase: PHASE1 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug targets tough cancers with KRAS G12D mutation
Disease control Recruiting nowUNLOCK ASP3082 is an open label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to ASP3082 in metastatic/locally advanced Non-Samll-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC) with the presenc…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC